Last updated on February 2020

Study of DS-7300a in Participants With Advanced Solid Malignant Tumors


Brief description of study

This study is in one single group of participants with advanced solid tumors who have not been cured by other treatments. It is the first time the drug will be used in humans, and will be in two parts.

The primary purpose of the parts are:

  • Dose Escalation Part: To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of DS-7300a.
  • Dose Expansion Part: To investigate the safety, tolerability and antitumor activity of DS-7300a.

This study is expected to last approximately 3.5 years from the time the first participant is enrolled to the time the last participant is off the study.

The number of treatment cycles is not fixed in this study. Participants who continue to benefit from the study treatment may continue, unless:

  • they withdraw
  • their disease gets worse
  • they experience unacceptable side effects.

Clinical Study Identifier: NCT04145622

Find a site near you

Start Over